Resumo:
En
|
Texto:
En
|
PDF:
En
Abstract In recent years, cold atmospheric plasma (CAP) is used for surface disinfection. However, little is known about its ability to improve biocompatibility of metallic surfaces when compared to thermal plasma methods. In this context, the study aimed to evaluate the response of human endothelial cells (Ea.hy926) on titanium surfaces treated by non-thermal plasma method and thermal plasma method under nitriding atmosphere. The wettability was characterized by the sessile drop method, the topography and roughness were evaluated by atomic force microscopy (AFM), and the microstructure by grazing angle X-ray diffraction (GIXRD). Endothelial cells were cultured and evaluated for morphology by scanning electron microscopy and viability by an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. CAP treatment reduced the contact angle of the Ti surface (13.43° ± 1.48; p<0.05), increasing hydrophilicity. Rz roughness was higher on the nitrided surface (220.44±20.30; p< 0.001) compared to the CAP treated surfaces (83.29 ± 11.61; p< 0.001) and polished (75.98 ±34.21a); p<0.001). The different applied plasma treatments created different titanium surfaces improving the biocompatibility of endothelial cells, however CAP results demonstrate its potential for biomedical applications, considering the low cost and ease of use of the technique, allowing surface treatments before clinical procedures. years (CAP disinfection However methods context Ea.hy926 Eahy926 Eahy Ea hy926 hy (Ea.hy926 nonthermal non atmosphere AFM, AFM , (AFM) Xray X ray GIXRD. GIXRD . (GIXRD) 34,5dimethylthiazol2yl2,5 345dimethylthiazol2yl25 dimethylthiazolyl 3 4,5 dimethylthiazol 2 yl 2,5 4 5 (3-[4,5-dimethylthiazol-2-yl]-2, bromide assay 13.43° 1343 13 43 (13.43 1.48 148 1 48 p<0.05, p005 p p<0.05 0 05 p<0.05) hydrophilicity 220.44±20.30 220442030 220 44 20 30 (220.44±20.30 0.001 0001 001 83.29 8329 83 29 (83.2 11.61 1161 11 61 75.98 7598 75 98 (75.9 ±34.21a 3421a a 34 21a ±34.21a) p<0.001. p0001 p<0.001 p<0.001) applications technique procedures Ea.hy92 Eahy92 hy92 (Ea.hy92 (AFM (GIXRD 5dimethylthiazol2yl2 34,5dimethylthiazol2yl2, 345dimethylthiazol2yl2 45 4, 25 2, (3-[4,5-dimethylthiazol-2-yl]-2 13.43 134 (13.4 1.4 14 p00 p<0.0 220.44±20.3 22044203 22 (220.44±20.3 0.00 000 00 83.2 832 8 (83. 11.6 116 6 75.9 759 7 9 (75. p000 p<0.00 Ea.hy9 Eahy9 hy9 (Ea.hy9 5dimethylthiazol2yl 34,5dimethylthiazol2yl2 345dimethylthiazol2yl (3-[4,5-dimethylthiazol-2-yl]- 13.4 (13. 1. p0 p<0. 220.44±20. 2204420 (220.44±20. 0.0 83. (83 11. 75. (75 Ea.hy (Ea.hy 34,5dimethylthiazol2yl (3-[4,5-dimethylthiazol-2-yl] 13. (13 p<0 220.44±20 220442 (220.44±20 0. (8 (7 (3-[4,5-dimethylthiazol-2-yl (1 220.44±2 22044 (220.44±2 ( 220.44± 2204 (220.44± 220.44 (220.44 220.4 (220.4 220. (220. (220 (22 (2